李炜 青年编委

学术贡献

• 1、1. Wei Li#, Li Wan. Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China. Expert Review of Pharmacoeconomics & Outcomes Research. 2024; 1-8.
• 2、2. Wei Li#, Li Wan, Jiangyan Zhang. Cost-effectiveness of tislelizumab plus chemotherapy vs chemotherapy as first-line treatment of PD-L1 positive advanced gastric or gastroesophageal junction adenocarcinoma from a Chinese perspective. Expert Rev Gastroenterol Hepatol. 2024; 1-9.
• 3、3. Wei Li, Lu She, Muyu Zhang, et al. The associations of IGF2, IGF2R and IGF2BP2 gene polymorphisms with gestational diabetes mellitus: A case-control study. PLoS One. 2024;19(5): e0298063.
• 4、4. Wei Li#, Li Wan. Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China. BMJ Open. 2023; 13: e074245.
• 5、5. Wei Li#, Li Wan. A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China. PLoS One. 2023;18(6): e0286595.
• 6、6. Huang C#, Guo Y#, Li W#, et al. Association of the CDKAL1 gene polymorphism with gestational diabetes mellitus in Chinese women. BMJ Open Diabetes Res Care. 2023;11(2): e003164.
• 7、7. Wei Li#, Li Wan. Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China. Frontiers in public health. 2022; 10: 1015702.
• 8、8. Jianqiong Liu#, Wei Li#, Bei Liu, et al. Melatonin receptor 1B genetic variants on susceptibility to gestational diabetes mellitus: A hospital-based case-control study in Wuhan, central China. Diabetes Metab Syndr Obes. 2022; 15:1207-1216.
• 9、9. Pei Zhang#, Mengyao Deng#, Wei Li#, et al. The correlation between transcription factor 7-like 2 gene polymorphisms and susceptibility of gestational diabetes mellitus in the population of central China: A case-control study. Frontiers in endocrinology. 2022;13, 916590.
• 10、10. Wei Li, Li Wan, Shaojun Duan, Jingjing Xu. Bibliometric analysis of toll-like receptor agonists associated with cancer therapy. Medicine. 2022; 101(1): e28520.
• 11、11. Lu She#, Wei Li#, Yan Guo#, Jia Zhou, et al. Association of glucokinase gene and glucokinase regulatory protein gene polymorphisms with gestational diabetes mellitus: a case-control study. Gene.2022; 824:146378.
• 12、12. Jianqiong Liu#; Qiong Dai#; Wei Li; Yan Guo, et al. Association of vitamin D receptor gene polymorphisms with gestational diabetes mellitus-a case control study in Wuhan, China, BMC Pregnancy Childbirth. 2021, 21(1): 142.
• 13、13. Wei Li, Mengzhu Zheng, Shuangping Wu, et al. Benserazide, a peripheral dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2. J Exp Clin Cancer Res. 2017; 36 (1): 58.
• 14、14. Mei Yang, Songxu Peng, Wei Li, et al. Relationships between plasma leptin levels, leptin G2548A, leptin receptor Gln223Arg polymorphisms and gestational diabetes mellitus in Chinese population. Sci Rep. 2016; 6:23948.
• 15、15. Mei Yang, Wei Li, Yukai Du. Elevated homocysteine levels in mothers with neural tube defects: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2017;30(17):2051-2057.
• 16、16. 李 炜,万 蒞,杨 梅*. PBL教学法在预防医学专业中应用的文献计量学分析. 卫生职业教育. 2021, 39(16):88-90.
• 17、17. 李炜,向俊,易晶,杨梅,万蒞,陈伦*.基于CNKI的2000-2018年我国抗生素滥用的文献计量学分析. 中国社会医学杂志. 2021, 38(3):344-346.
• 18、18. 李炜,邓梦瑶,唐昭,周伽，万蒞,杨梅*.基于CNKI数据库的2009-2017年出生缺陷研究论文的文献计量学分析. 中国社会医学杂志.2020, 37(6):654-656.
• 19、19. 12. 唐昭, 李炜, 周伽, 邓梦瑶, 向俊, 焦婷, 杨梅*. CDKAL1 基因 rs7754840 和 rs7756992 位点多态性与妊娠期糖尿病相关性的 Meta 分析. 现代预防医学. 2020, 47(6):1124-1129